HALDOL DECANOATE

This brand name is authorized in Austria, Australia, Germany, Ireland, Malta, United Kingdom, United States

Active ingredients

The drug HALDOL DECANOATE contains one active pharmaceutical ingredient (API):

1 Haloperidol decanoate UNII AC20PJ4101 - HALOPERIDOL DECANOATE

Haloperidol is an antipsychotic belonging to the butyrophenones group. It is a potent central dopamine type 2 receptor antagonist, and at recommended doses, has low alpha-1 antiadrenergic activity and no antihistaminergic or anticholinergic activity. Read about Haloperidol

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
HALDOL DECANOATE Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/Old

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N05AD01	Haloperidol	N Nervous system → N05 Psycholeptics → N05A Antipsychotics → N05AD Butyrophenone derivatives
Discover more medicines within N05AD01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 2765M, 2766N
Country: DE	Bundesinstitut für Arzneimittel und Medizinprodukte	Identifier(s): 02376695, 02376703, 14363060
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 37477, 37481
Country: IE	Health Products Regulatory Authority	Identifier(s): 27332, 27987
Country: MT	Medicines Authority	Identifier(s): AA018/02703, AA018/02704, AA565/15202
Country: US	FDA, National Drug Code	Identifier(s): 50458-253, 50458-254